ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 519

Marginal Structure Modeling of Association between Disease Activity and Hospitalized Infection Among Patients in a Rheumatoid Arthritis Registry

Huifeng Yun1, Lang Chen1, Jason Roy2, Jeffrey D. Greenberg3 and Jeffrey R. Curtis1, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Pennsylvania, Philadelphia, PA, 3Hopital Hautepierre, Strasbourg, France

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: infection and rheumatoid arthritis (RA), Medicare

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Higher disease activity might be associated with a higher risk of developing infections among patients with rheumatoid arthritis (RA). Since no randomized trial has been conducted using disease activity as the main exposure, this association may be confounded due to the effects of other RA treatments or comorbidities. To examine the association between RA disease activity and hospitalized infection using data from the U.S. Corrona RA registry linked to Medicare claims data for outcome ascertainment. We hypothesized that patients who started in moderate disease activity and subsequently attained low disease activity or remission had lower rates of infection.

 

Methods: Using CORRONA RA patients with Medicare coverage in 2006-2014, we identified eligible patients who had at least one visit with moderate disease activity based on the clinical disease activity index (CDAI between 10 and 22). Hospitalized infection was assessed in Medicare data. Follow-up started at the second Corrona visit and ended at the earliest date of: hospitalized infection, high disease activity (CDAI >22), loss to follow-up, or 12/31/2014. We calculated the incidence rate of hospitalized infection for patients in remission, low and moderate disease activity and estimated the effect of CDAI on hospitalized infection by controlling for time-dependent confounders using marginal structural models (MSM). Each observation was weighted using stabilized inverse-probability-of-treatment weights (IPTW), truncated at the 1st and 99th percentile.

Results: A total of 1,618 RA patients were eligible for analysis, for which 212 hospitalized infections were identified over mean follow-up of 2.2 years. These patients had mean (SD) age of 69.0 (10.0) years and 77.2% were female.  The crude incidence of hospitalized infection was 4.0 per 100 person years for patients in remission, 7.1 for low disease activity and 7.for in moderate disease activity. Using MSMs, and referent to being in remission, the hazard ratio of hospitalized infection associated with moderate disease activity was 1.19 (95% CI: 0.42-3.42) and for low disease activity was 0.78 (95% CI: 0.37-1.67). Baseline factors that were significantly associated with an increased risk for infection included older age, duration of RA, glucocorticoid use, and history of hospitalized infection.

Conclusion: In rheumatoid arthritis patients, the crude incidence of hospitalized infection was higher for patients in low or moderate disease activity compared to those in remission. However, these differences were greatly attenuated after controlling for confounding using marginal structural models to account for the interplay of disease activity, RA treatments, treatment switching, and other potential confounders.

Table : Events, absolute incidence rate and hazard ratios of hospitalized infection by disease activity

Disease activity

Events

Incidence rate per 100 person years

Unadjusted Hazard Ratio (95% CI) without weight*

 

Adjusted HR (95% CI) without IPTW weighting**

Unadjusted HR (95% CI) with stabilized weights†

Adjusted HR (95% CI) with stabilized weights†

Moderate

105

7.5

1.89 (1.32-2.71)

1.59 (1.09-2.32)

1.56 (0.61-4.01)

1.19 (0.42-3.42)

Low

95

7.1

1.69 (1.19-2.38)

1.50 (1.04-2.15)

0.86 (0.37-1.96)

0.78 (0.37-1.67)

remission

13

4.0

Ref

Ref

 

Ref

* Without adjustment and without weight

** Adjusted baseline and time-varying characteristics, but did not apply weight

† Adjusted baseline and time-varying characteristics with stabilized weight

 

 


Disclosure: H. Yun, Bristol Myers Squibb, 2; L. Chen, None; J. Roy, None; J. D. Greenberg, Corrona, LLC, 1, 5; J. R. Curtis, AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Janssen, Lilly, Myriad, Pfizer, Radius, Roche/Genentech, UCB, 2,AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Janssen, Lilly, Myriad, Pfizer, Radius, Roche/Genentech, UCB, 5.

To cite this abstract in AMA style:

Yun H, Chen L, Roy J, Greenberg JD, Curtis JR. Marginal Structure Modeling of Association between Disease Activity and Hospitalized Infection Among Patients in a Rheumatoid Arthritis Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/marginal-structure-modeling-of-association-between-disease-activity-and-hospitalized-infection-among-patients-in-a-rheumatoid-arthritis-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/marginal-structure-modeling-of-association-between-disease-activity-and-hospitalized-infection-among-patients-in-a-rheumatoid-arthritis-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology